Neuralstem (CUR) Trading Up 8.9%

Neuralstem, Inc. (NASDAQ:CUR) shares were up 8.9% on Friday . The company traded as high as $2.36 and last traded at $2.08. Approximately 2,552,100 shares traded hands during mid-day trading, an increase of 321% from the average daily volume of 606,638 shares. The stock had previously closed at $1.91.

Separately, S&P Equity Research reduced their price target on Neuralstem from $2.26 to $1.91 in a report on Thursday.

The stock has a market cap of $31.50, a price-to-earnings ratio of -1.25 and a beta of 1.60.

An institutional investor recently raised its position in Neuralstem stock. Vanguard Group Inc. increased its holdings in shares of Neuralstem, Inc. (NASDAQ:CUR) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 345,346 shares of the company’s stock after purchasing an additional 3,853 shares during the quarter. Vanguard Group Inc. owned 2.90% of Neuralstem worth $2,000,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.05% of the company’s stock.

WARNING: “Neuralstem (CUR) Trading Up 8.9%” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit